Published in The Lancet, results of the phase III COMPETE clinical trial show that the targeted radiotherapeutic agent [¹⁷⁷Lu]Lu-edotreotide significantly prolonged progression-free survival in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) when compared to targeted therapy with everolimus.

In a post hoc analysis of 210 ICU-admitted patients from the French multicenter COMBAT cohort, nearly half of survivors of community-acquired bacterial meningitis still had unfavourable functional outcomes 1 year after intensive care. Hearing loss, depressive symptoms, and impaired physical quality of life were common, while fewer than half resumed work. The SOFA score on day 3 independently predicted 30-day mortality, highlighting the value of repeated organ function assessment.

A UTHealth Houston neurologist was among a group of two dozen healthcare professionals from across the globe who developed an international certification program designed to improve rehabilitation care among stroke survivors.